Dana-Farber Cancer Institute | Strategic Alliance Partners

September 09, 2020

Atish D. Choudhury, MD, PhD, discusses antiandrogen treatment selection in nonmetastatic castration-resistant prostate cancer.

September 09, 2020

David A. Braun, MD, PhD, discusses findings from a pooled analysis of 3 clinical trials evaluating the potential impact of immunophenotypes, somatic mutations, and chromosomal alterations on response to PD-1 inhibition and recurrence in patients with renal cell carcinoma.

September 08, 2020

Bradley McGregor, MD, discusses the need to develop novel, actionable targets in renal cell carcinoma.

September 04, 2020

A supplemental biologics license application has been filed with the FDA for axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma following 2 or more previous lines of systemic therapy.

September 02, 2020

Caron Jacobson, MD, discusses the high-risk patient population within relapsed/refractory indolent non-Hodgkin lymphoma included in the phase 2 ZUMA-5 study.

September 02, 2020

Findings from the phase 3 STAMPEDE, LATITUDE , and TITAN studies, brought to light the utility of second-generation androgen receptor inhibitors.

September 02, 2020

Paul L. Nguyen, MD, discusses the role of radiation therapy in high-risk prostate cancer.

August 31, 2020

Today, we had the pleasure of sitting down with a group of experts in genitourinary cancers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Moffitt Cancer Center to discuss a malignancy that is not often an everyday focus: penile cancer.

August 27, 2020

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.

August 26, 2020

Quoc-Dien Trinh, MD, discusses ​the challenges of the novel coronavirus disease 2019 pandemic in prostate cancer. 

August 26, 2020

Quoc-Dien Trinh, MD, discusses surgical considerations for patients with prostate cancer in light of the novel coronavirus disease pandemic.

August 25, 2020

Bradley McGregor, MD, discusses the evolving treatment landscape of renal cell carcinoma.

August 25, 2020

Ann H. Partridge, MD, MPH, discusses the role of genomic testing in breast cancer.

August 24, 2020

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

August 24, 2020

Steven Lee Chang, MD, discusses the impact of the coronavirus disease 2019 on the surgical management of patients with genitourinary cancers.

August 21, 2020

Bradley A. McGregor, MD, sheds light on recently approved agents, as well as a multitude of novel therapies on the horizon, that appear to spell out a promising future for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

August 21, 2020

Toni K. Choueiri, MD, discusses the novel coronavirus disease, which continues to impact the care of patients with metastatic renal cell carcinoma and other cancers in a multitude of ways.

August 20, 2020

David A. Reardon, MD, discusses the design of a phase 1/2 trial with INO-5401 and INO-9012 in glioblastoma.

August 20, 2020

Praful K. Ravi, MD, discusses the evolving treatment landscape of advanced bladder cancer.

August 20, 2020

Bradley McGregor, MD, discusses some of the recent approaches that have emerged in bladder cancer and renal cell carcinoma, as well as anticipated developments in each field.